CJC-1295 + Ipamorelin research: what the evidence actually covers

Evidence summary: CJC-1295 and ipamorelin signal through different receptors associated with growth-hormone release: the GHRH receptor and GHS-R1a, respectively. That creates a mechanistic reason to study them together. However, the foundational studies evaluated ipamorelin alone in animals and long-acting CJC-1295 with DAC in humans—not the commercial no-DAC blend.

Key findings

  • The components target different receptors but converge on growth-hormone release.
  • Human CJC-1295 pharmacokinetic findings belong to the DAC form, not modified GRF 1-29.
  • No controlled study cited here tested the combined 1:1 vial formulation.

Two pathways that converge on one endocrine output

CJC-1295 without DAC is a GHRH analog intended to activate the pituitary GHRH receptor and its cAMP signalling pathway. Ipamorelin is a growth-hormone secretagogue that activates the ghrelin receptor GHS-R1a and signals through a different intracellular route.

Because both inputs reach pituitary somatotrophs, researchers can ask whether combined receptor activation changes GH release. Receptor complementarity supports a hypothesis; it does not prove synergy or a particular outcome.

What the ipamorelin evidence established

Raun and colleagues characterised ipamorelin in rat and swine experiments. It released GH without the marked ACTH and cortisol responses associated with earlier GHRPs, which led the authors to describe it as selective.

This was preclinical, single-compound work. It did not test CJC-1295, a blend, human outcomes or a 1:1 formulation.

Why DAC status changes the interpretation

The principal human CJC-1295 studies tested a Drug Affinity Complex form that binds albumin and produces prolonged exposure. Those studies reported multi-day pharmacokinetics and sustained changes in GH and IGF-1 while preserving pulsatility.

The blend discussed here contains CJC-1295 without DAC, commonly called modified GRF 1-29. Transferring the DAC form's reported half-life or exposure profile to the no-DAC component is scientifically inaccurate.

The missing blend-specific evidence

The primary literature cited here does not include a controlled study of CJC-1295 without DAC and ipamorelin administered as a combined commercial formulation. There is no published blend-specific pharmacokinetic profile, optimized ratio or demonstrated clinical outcome in these papers.

A 5mg plus 5mg vial is a product specification. It should not be represented as a dose-ranging result or a recommendation for use.

Building an interpretable laboratory comparison

A useful design separates the component variables: CJC-1295 form, ipamorelin exposure, receptor expression, species, sampling schedule and downstream measurements. Separate-component controls are needed before an observation can be attributed to the combination.

Because GH release is pulsatile, serial measurements or integrated endpoints are more informative than one isolated timepoint. Lot identity, measured purity, preparation and storage history should also be recorded.

Continue to the full evidence guide

Read the complete CJC-1295 + Ipamorelin guide

Frequently asked questions

Why are CJC-1295 and ipamorelin studied together?

They activate different receptors associated with GH release, creating a receptor-level combination hypothesis.

Was the commercial blend tested in a controlled study?

No controlled study of the combined 1:1 formulation is included in the primary evidence reviewed here.

Is CJC-1295 with DAC the same as the blend component?

No. The blend uses the no-DAC form, while the cited human pharmacokinetic studies tested long-acting CJC-1295 with DAC.

What evidence supports ipamorelin selectivity?

Animal experiments reported GH release without marked ACTH or cortisol increases at GH-releasing exposures.

Is the blend approved for human use?

No. It is supplied strictly for laboratory research and is not for human or veterinary use.

Primary references

  1. Raun K, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998. PubMed 9849822
  2. Teichman SL, et al. Prolonged stimulation of growth hormone and insulin-like growth factor I secretion by CJC-1295 in healthy adults. J Clin Endocrinol Metab. 2006. PubMed 16352683
  3. Ionescu M, Frohman LA. Pulsatile secretion of growth hormone persists during continuous stimulation by CJC-1295. J Clin Endocrinol Metab. 2006. PubMed 17018654

Related research materials

Research Use Only. Not for human or veterinary use. This page is not dosing or medical guidance.